SG/PUT/BRISTOL-MYERS SQUIBB/50/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 03:47:51 2024-07-05 pm EDT | ||
| 0.95 EUR | +3.26% |
|
| Current month | +13.10% | ||
| 1 month | +11.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 0.95 | +3.26% |
| 24-07-04 | 0.92 | -3.16% |
| 24-07-03 | 0.95 | +1.06% |
| 24-07-02 | 0.94 | +8.05% |
| 24-07-01 | 0.87 | +3.57% |
Delayed Quote Deutsche Boerse AG
Last update July 05, 2024 at 03:47 pm EDT
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SV6QT2 |
| ISIN | DE000SV6QT22 |
| Date issued | 2023-05-24 |
| Strike | 50 $ |
| Maturity | 2024-09-20 (76 Days) |
| Parity | 10 : 1 |
| Emission price | 0.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.98 € |
|---|---|
| Lowest since issue | 0.13 € |
| Spread | 0.01 € |
| Spread % | 1.04% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
39.66
USD
Average target price
53.19
USD
Spread / Average Target
+34.13%
- Stock Market
- Warrants
- Warrant
